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ORIGINAL ARTICLE
BACKGROUND: Chagas’ disease is an important cause of 
cardiomyopathy in Latin America. We aimed to compare clinical 
characteristics and outcomes in patients with heart failure (HF) with 
reduced ejection fraction caused by Chagas’ disease, with other 
etiologies, in the era of modern HF therapies.
METHODS AND RESULTS: This study included 2552 Latin American 
patients randomized in the PARADIGM-HF (Prospective Comparison 
of ARNI With ACEI to Determine Impact on Global Mortality and 
Morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize 
Outcomes in Patients With Heart Failure) trials. The investigator-reported 
etiology was categorized as Chagasic, other nonischemic, or ischemic 
cardiomyopathy. The outcomes of interest included the composite of 
cardiovascular death or HF hospitalization and its components and death 
from any cause. Unadjusted and adjusted Cox proportional hazards 
models were performed to compare outcomes by pathogenesis. There 
were 195 patients with Chagasic HF with reduced ejection fraction, 
1300 with other nonischemic cardiomyopathy, and 1057 with ischemic 
cardiomyopathy. Compared with other etiologies, Chagasic patients were 
more often female, younger, and had lower prevalence of hypertension, 
diabetes mellitus, and renal impairment (but had higher prevalence of 
stroke and pacemaker implantation) and had worse health-related quality 
of life. The rates of the composite outcome were 17.2, 12.5, and 11.4 
per 100 person-years for Chagasic, other nonischemic, and ischemic 
patients, respectively—adjusted hazard ratio for Chagasic versus other 
nonischemic: 1.49 (95% confidence interval, 1.15–1.94; P=0.003) and 
Chagasic versus ischemic: 1.55 (1.18–2.04; P=0.002). The rates of all-
cause mortality were also higher.
CONCLUSIONS: Despite younger age, less comorbidity, and 
comprehensive use of conventional HF therapies, patients with Chagasic 
HF with reduced ejection fraction continue to have worse quality of 
life and higher hospitalization and mortality rates compared with other 
etiologies.
CLINICAL TRIAL REGISTRATION: PARADIGM-HF: URL: http://www.
clinicaltrials.gov. Unique identifier: NCT01035255; ATMOSPHERE: URL: 
http://www.clinicaltrials.gov. Unique identifier: NCT00853658.
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Chagas’ disease, caused by the protozoan Trypano-soma cruzi, is estimated to affect 6 to 7 million people in Latin America and ≈300 000 people in 
the Unites States of America.1–10 Indeed, concern about 
the growing prevalence of T. cruzi infection has led to 
screening of donations to the blood banks in the Unit-
ed States of America.11 More recently, cases of Chagas’ 
disease have been reported in Europe.12 Up to 30% of 
affected individuals exhibit evidence of a chronic car-
diomyopathy 2 to 3 decades after infection, ranging 
from asymptomatic ECG abnormalities to structural 
heart disease, with some patients ultimately developing 
heart failure with a reduced ejection fraction (HFrEF).1–10 
Despite the high prevalence of Chagas’ disease, little is 
known about the morbidity and mortality in patients 
with HFrEF caused by Chagas’ disease, compared with 
other etiologies, especially in the modern era of heart 
failure (HF) therapies.13–21 We pooled the 2 largest and 
most recent trials in HFrEF, the PARADIGM-HF (Prospec-
tive Comparison of ARNI With ACEI to Determine Im-
pact on Global Mortality and Morbidity in Heart Fail-
ure) and the ATMOSPHERE (Aliskiren Trial to Minimize 
Outcomes in Patients With Heart failure Trial), to look 
further into investigator-reported Chagasic HF in Latin 
America.22,23
METHODS
Study Population
This study consisted of 2552 Latin American patients with 
HFrEF randomized in the PARADIGM-HF and ATMOSPHERE 
trials. The design and primary results of both studies have 
been published.22,23 Briefly, in PARADIGM-HF patients had 
New York Heart Association class II to IV symptoms, a left 
ventricular ejection fraction ≤40% (changed to ≤35% by 
amendment), and an elevated plasma natriuretic peptide level 
(B-type natriuretic peptide [BNP] ≥150 pg/mL or NT-proBNP 
[N-terminal pro-B-type natriuretic peptide] ≥600 pg/mL). 
Patients with lower natriuretic peptide levels (BNP ≥100 pg/mL 
or NT-proBNP ≥400 pg/mL) were eligible if they had been hos-
pitalized for HF within 12 months. Patients were required to 
receive an angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker (equivalent to enalapril ≥10 mg daily), 
along with a stable dose of a β-blocker (unless contraindicated) 
and a mineralocorticoid receptor antagonist (if indicated), for 
at least 4 weeks before screening. In ATMOSPHERE, patients 
had New York Heart Association class II to IV symptoms, HF 
with a reduced left ventricular ejection fraction (≤35%), and 
an elevated plasma natriuretic peptide level (same criteria as 
in PARADIGM-HF). Patients were required to be treated with 
an angiotensin-converting enzyme inhibitor (equivalent to 
enalapril ≥10 mg daily), a stable dose of a β-blocker (unless 
contraindicated) for at least 4 weeks before screening, and 
could be treated with a mineralocorticoid receptor antago-
nist if felt to be indicated by the investigator. Both trials used 
a composite of cardiovascular death or HF hospitalization as 
the primary outcome. Both trials were approved by the eth-
ics committee in each study center. All patients gave written 
informed consent.
Primary Pathogenesis of HF
The primary HF etiology was collected at the screening visit 
using a similar, structured, case report form in both trials. We 
used this information to categorize the patients into 3 mutu-
ally exclusive subgroups (ie, investigator-reported Chagas’ 
disease, other nonischemic cardiomyopathy, and ischemic 
cardiomyopathy).
Study Outcomes
The outcomes of interest in this study included a composite 
of cardiovascular death or first HF hospitalization and its com-
ponents, as well as death from any cause. We also examined 
the 2 major modes of cardiovascular death (ie, sudden death 
and pump failure death).
Statistical Analyses
Baseline characteristics were summarized as means with SDs 
for continuous variables and numbers with percentages for 
categorical variables. Baseline characteristics were compared 
across HF pathogenesis categories using ANOVA for continu-
ous variables with Bonferroni correction for multiple com-
parisons and the χ2 test for categorical variables. The Kansas 
City Cardiomyopathy Questionnaire clinical summary score24 
and NT-proBNP were not normally distributed and therefore 
were summarized as medians with the first and third quartile 
(Q1–Q3) and analyzed using Kruskal–Wallis test with Dunn 
test and Bonferroni correction for multiple comparisons. 
Event rates for each outcome according to HF pathogenesis 
were calculated per 100 patient-years of follow-up. The pro-
portional hazards (Cox) regression analysis was used to calcu-
late the hazard ratio for each outcome with the comparisons 
of Chagas’ disease versus nonischemic cardiomyopathy and 
Chagas’ disease versus ischemic cardiomyopathy. The propor-
tional hazards regression analyses were also performed with 
adjustment for treatment assignment, age, sex, left ventricu-
lar ejection fraction, New York Heart Association class, and 
NT-proBNP (log transformed) to account for the confounding. 
WHAT IS NEW?
• Patients with heart failure with a reduced ejection 
fraction because of Chagas’ disease continue to 
have worse quality of life and higher hospitaliza-
tion and mortality rates, compared with other 
pathogeneses, despite their younger age, less 
comorbidity, and comprehensive use of conven-
tional heart failure therapies.
WHAT ARE THE CLINICAL  
IMPLICATIONS?
• Better understanding of the mechanism and natu-
ral history of Chagasic heart failure is needed in 
the future studies to identify strategies for improv-
ing its prognosis.
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Within-trial clustering was taken into consideration with the 
use of shared frailty models. A 2-sided P<0.05 was considered 
statistically significant. All statistical analyses were performed 
using Stata version 14 (Stata Corp, College Station, TX).
RESULTS
Overall, 195 patients (7.6% of the total) were reported 
to have Chagasic cardiomyopathy, 1300 (51%) another 
type of nonischemic cardiomyopathy, and 1057 (41%) 
ischemic HFrEF. The largest number of Chagas’ patients 
were enrolled in Brazil (n=112; accounting for 22.7% 
of all patients randomized in that country), followed by 
Argentina (n=60; 7.2%) and Colombia (n=16; 5.2%; 
Table I in the Data Supplement).
Baseline Characteristics
The baseline characteristics of patients with Chagasic 
HFrEF compared with those with other nonischemic 
cardiomyopathy and ischemic cardiomyopathy are 
shown in Table 1.
Notable differences included the younger age of indi-
viduals with Chagasic cardiomyopathy, their lower sys-
tolic blood pressure, lower body mass index, and lower 
prevalence of hypertension and diabetes mellitus com-
pared with patients in the other etiology subgroups. 
Individuals with Chagasic HFrEF were more likely to be 
female and have a history of stroke and renal impair-
ment than in the other etiology subgroups (especially 
compared with patients with other nonischemic HFrEF). 
Right bundle branch block was much more common in 
patients with Chagasic cardiomyopathy compared with 
patients with other causes of nonischemic and ischemic 
HFrEF whereas left bundle branch block was less com-
mon in patients with Chagas’ disease compared with 
the other groups.
Patients with Chagasic HFrEF were much more 
likely than other patients to have a history of pace-
maker implantation. β-Blockers were used less often in 
patients with Chagasic cardiomyopathy compared with 
other types of HFrEF, but anticoagulant and, especially, 
amiodarone, treatment was used more frequently.
Patients with Chagasic HFrEF reported significantly 
worse health-related quality of life as evaluated using 
the Kansas City Cardiomyopathy Questionnaire with 
median (Q1–Q3) values of 85 (72–94), 87 (74–96), and 
82 (70–92) in patients with ischemic, other nonisch-
emic, and Chagasic cardiomyopathy.
Clinical Outcomes
The rates of the primary composite outcome, its com-
ponents, and all-cause death are shown in Table  2 
and the Figure. Patients with Chagasic HFrEF had a 
higher unadjusted and adjusted risk of the primary 
outcome compared with each of the other pathogen-
ic categories, with the adjusted risk ≈50% greater. 
The adjusted risk of both cardiovascular and all-cause 
death was ≈40% greater in patients with Chagasic 
cardiomyopathy than in patients with ischemic HFrEF. 
The adjusted risk of all-cause death was also higher 
than in patients with nonischemic HFrEF although the 
risk of cardiovascular death was not statistically sig-
nificantly higher.
We also examined the 2 main modes of cardiovas-
cular death (Table 2). The risk of sudden death did not 
differ significantly by etiology although in Chagasic 
patients this mode of death was relatively less common 
than in patients with ischemic cardiomyopathy and rela-
tively more common than in patients with other causes 
of nonischemic cardiomyopathy (but these trends were 
not statistically significant). Conversely, pump failure 
death was more common in Chagasic patients, espe-
cially when compared with ischemic cardiomyopathy 
patients.
Patients with a Chagasic pathogenesis had a sub-
stantially elevated risk (60%–80% higher) of HF hospi-
talization compared with each of the other pathogenic 
categories. In sensitivity analyses, additional adjustment 
for right and left bundle branch block did not materi-
ally alter the difference in risk between patients with 
Chagas’ disease and those in the other groups (data 
not shown).
DISCUSSION
Approximately 8% of patients enrolled in ATMOSPHERE 
and PARADIGM-HF in Latin America had HFrEF attrib-
uted to Chagas’ disease. Although higher rates have 
been reported in some registers from more endemic 
regions, the proportion in our study is consistent with 2 
prior studies from the GESICA group (Grupo de Estudio 
de la Sobrevida en la Insuficiencia Cardiaca en Argen-
tina) where 9.3% and 5.7%, respectively, of patients 
had HFrEF because of Chagas’ disease.25,26 Our cases 
also showed a geographic distribution consistent with 
the known epidemiology of Chagas’ cardiomyopathy.27
Although several prior studies have compared indi-
viduals with Chagasic HFrEF to others with ischemic or 
nonischemic cardiomyopathy (but not both concomi-
tantly), these have been mainly single-center reports of 
often highly selected cohorts (eg, transplant referrals) 
usually markedly undertreated by contemporary stan-
dards.12–20,28 These prior reports included between 25 
and 246 patients with Chagas’ cardiomyopathy and 
50 to 454 patients in the comparator group, usually 
did not report detailed characterization of participants 
(eg, in relation to prior history and biomarkers) and 
often did not adjust for differences in a multivariable 
analysis when comparing outcomes across etiologic 
groups.13–21,28
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Table 1. Baseline Characteristics in Patients With Chagasic Heart Failure Compared With Those With 
Nonischemic Cardiomyopathy and Those With Ischemic Cardiomyopathy in Latin America in the 
Combined Data Sets of PARADIGM-HF and ATMOSPHERE
Chagasic
Other 
Nonischemic Ischemic P Value
n=195 n=1300 n=1057
Chagasic 
vs Other 
Nonischemic
Chagasic  
vs Ischemic
Age, y 59.6±10.7 61.1±12.5 65.8±10.1 0.291 <0.0001
Male sex, n (%) 129 (66.2) 897 (69.0) 828 (78.3) 0.424 <0.0001
Race, n (%)    <0.0001 <0.0001
  White 107 (54.9) 554 (42.6) 449 (42.5)   
  Black 34 (17.4) 147 (11.3) 46 (4.4)   
  Asian 0 (0.0) 0 (0.0) 2 (0.2)   
  Other 54 (27.7) 599 (46.1) 560 (53.0)   
BMI, kg/m2 26.0±4.6 27.6±5.2 27.4±4.5 <0.0001 0.001
Blood pressure, mm Hg
  Systolic 111.4±12.5 120.3±15.9 120.7±15.0 <0.0001 <0.0001
  Diastolic 71.4±8.8 74.3±10.7 72.9±10.1 0.001 0.206
Heart rate, beats/min 65.5±10.3 72.0±12.0 70.2±11.3 <0.0001 <0.0001
LVEF, % 28.5±6.2 27.1±6.3 28.5±6.1 0.015 0.999
NYHA class, n (%)    0.103 0.070
  I 11 (5.7) 80 (6.2) 47 (4.5)   
  II 170 (87.6) 1054 (81.1) 868 (82.2)   
  III 13 (6.7) 165 (12.7) 140 (13.3)   
  IV 0 (0.0) 1 (0.1) 1 (0.1)   
Medical history, n (%)
  Current smoker 14 (7.2) 110 (8.5) 74 (7.0) 0.545 0.929
  Previous HF hospitalization 100 (51.3) 727 (55.9) 525 (49.7) 0.224 0.679
  Myocardial infarction 1 (0.5) 35 (2.7) 748 (70.8) 0.064 <0.0001
  Angina 4 (2.1) 35 (2.7) 223 (21.1) 0.600 <0.0001
  CABG or PCI 1 (0.5) 28 (2.2) 396 (37.5) 0.121 <0.0001
  Hypertension 85 (43.6) 874 (67.2) 739 (69.9) <0.0001 <0.0001
  Diabetes mellitus 15 (7.7) 290 (22.3) 341 (32.3) <0.0001 <0.0001
  Atrial fibrillation 63 (32.3) 380 (29.2) 182 (17.2) 0.380 <0.0001
  Stroke 27 (13.8) 56 (4.3) 88 (8.3) <0.0001 0.014
Medication/devices, n (%)
  Digitalis 75 (38.5) 543 (41.8) 284 (26.9) 0.382 0.001
  Diuretics 158 (81.0) 1086 (83.5) 785 (74.3) 0.381 0.044
  ACE inhibitor or ARB 113 (100.0) 699 (99.4) 616 (99.8) 0.422 0.668
  β-Blocker 166 (85.1) 1187 (91.3) 984 (93.1) 0.006 <0.0001
  MRA 133 (68.2) 763 (58.7) 539 (51.0) 0.011 <0.0001
  Antiplatelet 61 (31.3) 576 (44.3) 763 (72.2) 0.001 <0.0001
  Anticoagulant 54 (27.7) 285 (21.9) 161 (15.2) 0.073 <0.0001
  Amiodarone 80 (41.0) 150 (11.5) 100 (9.5) <0.0001 <0.0001
  Pacemaker 59 (30.3) 77 (5.9) 83 (7.9) <0.0001 <0.0001
  CRT 5 (2.6) 23 (1.8) 15 (1.4) 0.445 0.241
  ICD 15 (7.7) 40 (3.1) 48 (4.5) 0.001 0.064
(Continued )
Shen et al; Chagas’ Disease and Outcomes in Heart Failure
Circ Heart Fail. 2017;10:e004361. DOI: 10.1161/CIRCHEARTFAILURE.117.004361 November 2017 5
Despite these differences, it is possible to make 
some comparisons with our findings. In both the prior 
studies and in ours, Chagasic patients were notable by 
their younger age and lower preponderance of males 
(especially when compared with patients with ischemic 
HFrEF). The high prevalence of right bundle branch 
block, prior pacemaker implantation, and amiodarone 
use are also characteristic features of patients with 
Chagasic cardiomyopathy.29
Our cohort, recruited according to standardized trial 
inclusion and exclusion criteria, does, however, high-
light other striking differences. The low prevalence of 
diabetes mellitus and history of hypertension, com-
pared with patients with other nonischemic and isch-
emic HFrEF, is striking, and the latter is consistent with 
the much lower systolic blood pressure in the Chagasic 
group. Similarly, the markedly higher prevalence of pri-
or stroke (in the absence of a substantially higher preva-
lence of atrial fibrillation) is consistent with concerns 
about high risk of thromboembolism in patients with 
Chagasic cardiomyopathy (and reflected in the higher 
use of anticoagulant therapy in these individuals).30
We noted worse renal function in Chagasic patients, 
compared with the others, despite younger age and 
less diabetes mellitus and hypertension. Why this find-
ing has not been previously reported and the reason 
for it is uncertain, the greater use of mineralocorticoid 
receptor antagonist in Chagasic patients and lower sys-
tolic blood pressure may have played a role.
One finding which, notably, was not significantly dif-
ferent, with respect to etiology, was baseline NT-proBNP 
level (although this was numerically highest in the Cha-
ECG findings, n (%)
  Atrial fibrillation 37 (19.0) 283 (21.8) 114 (10.8) 0.367 0.001
  Left bundle branch block 23 (11.8) 402 (31.0) 228 (21.7) <0.0001 0.002
  Right bundle branch block 46 (23.6) 92 (7.1) 96 (9.1) <0.0001 <0.0001
  Q waves 7 (3.6) 70 (5.4) 311 (29.5) 0.288 <0.0001
  Left ventricular hypertrophy 7 (3.6) 334 (25.8) 187 (17.8) <0.0001 <0.0001
Laboratory measures
  eGFR, mL/min per 1.73 m2 69.2±19.8 75.1±28.0 70.1±21.8 0.006 0.999
  eGFR <60 mL/min per 1.73 m2, n (%) 67 (34.4) 334 (25.7) 345 (32.6) 0.011 0.639
  Serum creatinine, mg/dL 1.10±0.28 1.03±0.30 1.08±0.30 0.011 0.999
  NT-proBNP, pg/mL 1753 [793–3247] 1539 [840–3367] 1486 [808–2973] 0.999 0.583
Symptoms, signs, and HRQL, n (%)
  Dyspnea on effort 176 (90.7) 1113 (85.6) 921 (87.2) 0.054 0.171
  Dyspnea at rest 4 (2.1) 19 (1.5) 22 (2.1) 0.526 0.985
  Orthopnea 8 (4.1) 113 (8.7) 98 (9.3) 0.030 0.018
  Paroxysmal nocturnal dyspnea 4 (2.1) 40 (3.1) 49 (4.6) 0.435 0.101
  Fatigue 71 (36.6) 419 (32.2) 387 (36.6) 0.227 0.989
  Edema 23 (11.9) 198 (15.2) 185 (17.5) 0.217 0.052
  Jugular venous distention 24 (12.4) 192 (14.8) 168 (15.9) 0.376 0.209
  Third heart sound 9 (4.6) 105 (8.1) 61 (5.8) 0.092 0.527
  Rales 9 (4.6) 64 (4.9) 86 (8.1) 0.864 0.090
  KCCQ clinical summary score* 82 [70–92] 87 [74–96] 85 [72–94] 0.006 0.255
Plus–minus values are mean±SD. NT-proBNP and KCCQ clinical summary score are summarized as median (the first quartile to the third quartile). 
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ATMOSPHERE, Aliskiren Trial to Minimize Outcomes in Patients 
With Heart Failure; BMI, body mass index; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular 
filtration rate; HF, heart failure; HRQL, health-related quality of life; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy 
Questionnaire; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic 
peptide; NYHA, New York Heart Association; PARADIGM-HF, Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality 
and Morbidity in Heart Failure Trial; and PCI, percutaneous coronary intervention.
*Values of the KCCQ clinical summary score (on a scale from 0 to 100, with higher scores indicating better health-related quality of life) 
were available for 1101 patients with nonischemic cardiomyopathy, for 848 patients with ischemic cardiomyopathy, and for 189 patients with 
Chagas disease.
Table 1. Continued
Chagasic
Other 
Nonischemic Ischemic P Value
n=195 n=1300 n=1057
Chagasic 
vs Other 
Nonischemic
Chagasic  
vs Ischemic
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gasic patients). As NT-proBNP is the single most power-
ful prognostic variable in HF, it is interesting that out-
comes were so much worse for patients with Chagas’ 
disease. Why prognosis is worse is, therefore, not clear. 
Immune or inflammatory mechanisms might be rel-
evant or other biological or nonbiological issues might 
be important. For example, Chagas’ disease is more 
prevalent in more socioeconomically deprived popula-
tions and this may influence health and outcomes in a 
variety of ways.
Although the protocol for both PARADIGM-HF and 
ATMOSPHERE required β-blockers to be used in all 
patients unless not tolerated or contraindicated, fewer 
patients with Chagasic HFrEF (85%) were treated with 
an agent from this class than in the other nonischemic 
patients (91%) or in the ischemic group (93%). Nev-
ertheless, this is a much higher use than reported in 
most prior studies in Chagasic patients where the rate 
has been typically ≈40%, usually because of concerns 
about sinoatrial and conducting system disease.12–20 
Resting heart rate was notably lower (65 beats per 
minute) in our Chagasic patients, compared with the 
other nonischemic group (72 beats per minute) and 
ischemic group (70 beats per minute), despite the dif-
ferent rate of β-blocker use. However, amiodarone use 
(43%) was common in Chagasic patients (compared 
with 11% of patients in the other nonischemic group 
and 9% of those in the ischemic group). In addition, 
39% of Chagasic patients were also receiving a digitalis 
glycoside (compared with 42% of patients in the other 
nonischemic group and 27% of patients in the ischemic 
group). While the use of all 3 of these drugs might be 
concerning, especially in a condition associated with 
sinoatrial and conduction system disease, 30% of Cha-
gasic patients had a pacemaker and a few more had 
cardiac resynchronization therapy or an implantable 
cardioverter defibrillator.
Patients with HFrEF because of Chagas’ disease also 
differed from the others in terms of clinical outcomes. 
Specifically, their adjusted risk of death (cardiovascular 
or all-cause) was ≈40% higher than in the other etiol-
ogy groups and risk of HF hospitalization 60% to 80% 
greater (despite the higher risk of death). These findings 
are notable in 2 ways. First, they demonstrate the mark-
edly higher risk in patients with Chagasic cardiomyopa-
thy once HFrEF develops. In the recent BENEFIT (Evalu-
ation of the Use of Antiparasital Drug [Benznidazole] in 
the Treatment of Chronic Chagas’ Disease) trial, where 
among patients of a similar average age, only about a 
quarter of patients were in New York Heart Association 
functional class II or greater and only 17% of patients 
had a left ventricular ejection fraction <40%, the annual 
mortality rate was ≈3%.31 In our patients, it was 13%. 
However, the excess risk related to Chagas’ disease in 
our cohort was much less than suggested in prior stud-
ies.13–21 Whether this is because of the historical nature 
Table 2. Outcomes According to Pathogenesis in Latin America in the Combined Data Sets of PARADIGM-HF  
and ATMOSPHERE
Event, n (%)
Annual Rate, 
per 100 Person-Years (95% CI) Unadjusted HR (95% CI)* Adjusted HR (95% CI)*†
Chagasic 
(n=195)
Other 
Nonischemic 
(n=1300)
Ischemic 
(n=1057) Chagas
Other 
Nonischemic Ischemic
Chagasic 
vs Other 
Nonischemic
Chagasic vs 
Ischemic
Chagasic 
vs Other 
Nonischemic
Chagasic vs 
Ischemic
CV death 
or HFH
67 (34.4) 364 (28.0) 264 (25.0) 17.2 
(13.6–21.9)
12.5 
(11.3–13.8)
11.4 
(10.1–12.9)
1.37 
(1.06–1.78), 
P=0.017
1.48 
(1.13–1.94), 
P=0.004
1.49 
(1.15–1.94), 
P=0.003
1.55
(1.18–2.04), 
P=0.002
CV death 46 (23.6) 287 (22.1) 199 (18.8) 10.7 
(8.0–14.3)
9.2  
(8.2–10.4)
8.1 
(7.1–9.4)
1.17 
(0.86–1.60), 
P=0.314
1.32 
(0.96–1.82), 
P=0.092
1.30 
(0.95–1.78), 
P=0.097
1.44 
(1.04–2.00), 
P=0.027
HFH 37 (19.0) 175 (13.5) 115 (10.9) 9.5  
(6.9–13.1)
6.0 
(5.2–7.0)
5.0 
(4.1–6.0)
1.56 
(1.10–2.23), 
P=0.014
1.86 
(1.28–2.69), 
P=0.001
1.64 
(1.15–2.35), 
P=0.006
1.83 
(1.25–2.67), 
P=0.002
All-cause 
death
57 (29.2) 336 (25.9) 251 (23.7) 13.3 
(10.2–17.2)
10.8 
(9.7–12.0)
10.3 
(9.1–11.6)
1.24 
(0.94–1.64), 
P=0.131
1.30 
(0.97–1.73), 
P=0.077
1.36 
(1.02–1.80), 
P=0.035
1.43 
(1.06–1.91), 
P=0.017
Sudden 
death
14 (7.2) 101 (7.8) 96 (9.1) 3.3 
(1.9–5.5)
3.2 
(2.7–3.9)
3.9 
(3.2–4.8)
1.00 
(0.57–1.75), 
P=0.99
0.81 
(0.46–1.43), 
P=0.47
1.11 
(0.63–1.94), 
P=0.73
0.89 
(0.51–1.58), 
P=0.70
Pump 
failure 
death
16 (8.2) 83 (6.4) 41 (3.9) 3.7 
(2.3–6.1)
2.7 
(2.2–3.3)
1.7 
(1.2–2.3)
1.40 
(0.82–2.40), 
P=0.22
2.25 
(1.26–4.02), 
P=0.01
1.69 
(0.98–2.91), 
P=0.06
2.52 
(1.40–4.56), 
P=0.002
ATMOSPHERE indicates Aliskiren Trial to Minimize Outcomes in Patients With Heart Failure Trial; CI, confidence interval; CV, cardiovascular; HFH, heart failure 
hospitalization; HR, hazard ratio; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and 
PARADIGM-HF, Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure.
*Hazard ratios for combined data were adjusted for within-trial clustering.
†Adjusted covariates: treatment group, age, sex, LVEF, NYHA class, and log 2 base NT-proBNP.
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of prior studies (with less comprehensive therapy), less 
complete adjustment for other prognostic variables, 
smaller and less comprehensive comparator groups, 
or some other factor or factors is unknown. The most 
recent study to compare outcomes between patients 
with Chagasic cardiomyopathy and other patients was 
undertaken among Latin American Immigrants in the 
Los Angeles area.32 Although that study reported a >4-
fold higher risk of death or transplantation among Cha-
gasic patients compared with patients with other types 
of nonischemic cardiomyopathy, it included a total of 
135 patients, of which only 25 had Chagasic cardiomy-
opathy (and there were only a total of 20 events).
We were also able to examine the 2 principal modes 
of cardiovascular death in the 3 etiology groups stud-
ied. This analysis showed that the excess mortality risk 
in Chagasic patients was because of pump failure rather 
than sudden death (especially compared with patients 
with an ischemic etiology). Although this finding might 
seem surprising in a condition widely considered to be 
highly arrhythmogenic, it is consistent with the view 
that modern pharmacological therapy, by reducing the 
risk of sudden death, may have resulted in pump failure 
death becoming the major mode of death in Chagas’ 
disease.33 We have already highlighted the much great-
er use of β-blockers in the current compared with prior 
reports. The potential role of amiodarone in prevent-
ing sudden death in Chagas’s cardiomyopathy is more 
controversial.
As with any study of this type there are limitations. 
This was a post hoc analysis. HFrEF etiology was report-
ed by investigators and not verified in any way; how-
ever, the characteristics of the patients in the different 
etiologic subgroups were consistent with what would 
Figure. Kaplan–Meier curves for clinical outcomes according to heart failure etiology (Latin American patients in 
combined PARADIGM-HF [Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and 
Morbidity in Heart Failure] and ATMOSPHERE [Aliskiren Trial to Minimize Outcomes in Patients With Heart Failure 
Trial] data sets).  
Kaplan–Meier estimates of the probability of the death from cardiovascular causes or first hospitalization for heart failure (A), 
death from cardiovascular causes (B), first hospitalization for heart failure (C), and death from any cause (D). CV indicates 
cardiovascular; and HF, heart failure.
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be expected, suggesting valid categorization by inves-
tigators. The total number of patients with Chagasic 
HFrEF was relatively small but similar or larger than 
in other studies comparing etiologies. The protocol 
required patients to be treated with a β-blocker unless 
contraindicated or not tolerated and patients had to 
tolerate enalapril 10 mg twice daily and sacubitril/val-
sartan 97/103 mg twice daily before randomization, 
resulting in selection of patients who could tolerate 
these different treatments. We did not have data on 
socioeconomic status.
CONCLUSIONS
Despite their younger age, less comorbidity, and com-
prehensive use of conventional pharmacological thera-
pies for HFrEF, patients with Chagasic HFrEF continue 
to have worse quality of life and higher hospitalization 
and mortality rates compared with those with HFrEF 
because of other nonischemic and ischemic causes.
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